| Treatment Outcome of Olfactory Neuroblastoma: A Multicenter Study by the Korean Sinonasal Tumor and Skull Base Surgery Study Group |
Sang Duk Hong1
, Song I Park1,2
, Ji Heui Kim3
, Sung Jae Heo4
, Sung-Woo Cho5
, Tae-Bin Won5
, Hyun-Jin Cho6
, Dong Hoon Lee7
, Sue Jean Mun8
, Soo Kyoung Park9
, Yong-Wan Kim10
, Dong-Young Kim11
|
1Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Department of Otolaryngology-Head and Neck Surgery, Inje University Ilsan Paik Hospital and Inje University School of Medicine, Goyang, South Korea
3Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
4Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University Chilgok Hospital, Daegu, South Korea
5Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
6Department of Otorhinolaryngology, Gyeongsang National University Hospital, Jinju, South Korea
7Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School & Hwasun Hospital, Hwasun, South Korea
8Department of Otorhinolaryngology-Head and Neck Surgery, Pusan National University Yangsan Hospital, Yangsan, South Korea
9Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University, School of Medicine, Daejeon, South Korea
10Department of Otorhinolaryngology-Head & Neck Surgery, Inje University Haeundae Paik Hospital, Busan, South Korea
11Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea |
| Correspondence |
Dong-Young Kim ,Tel: +82-2-2072-2440, Fax: +82-2-745-2387, Email: dongkim@snu.ac.kr
|
|
Received: December 26, 2023; Revised: January 22, 2024 Accepted: February 26, 2024. Published online: February 26, 2024.
*Sang Duk Hong and Song I Park contributed equally to this work. |
|
|
|
| ABSTRACT |
Objectives
Due to the rarity of olfactory neuroblastoma (ONB), there is an ongoing debate about optimal treatment strategies, especially for early staged or locally advanced cases. Therefore, our study aims to explore experiences from multiple centers, focusing on factors that influence the oncological outcomes of ONB.
Methods
We retrospectively analyzed 195 ONB patients treated at nine tertiary hospitals in South Korea between December 1992 and December 2019. Kaplan-Meier survival analysis was used to evaluate oncological outcomes, and the Cox proportional hazards regression model was employed to analyze prognostic factors for survival outcomes. Furthermore, we conducted 1:1 nearest-neighbor matching to investigate differences in clinical outcomes according to the use of neoadjuvant chemotherapy.
Results
In our cohort, the 5-year overall survival rate (OS) was 78.6%, and the 5-year disease-free survival rate (DFS) was 62.4%. The Cox proportional hazards model revealed that the mKadish stage and Dulguerov T status were significant for DFS, while the mKadish stage and Hyams grade were identified as prognostic factors for OS. The subgroup analyses indicated a trend toward improved 5-year DFS with dural resection in mKadish A and B cases, even though that result was statistically insignificant. Induction chemotherapy did not provide a survival benefit in this study after matching for the mKadish stage and nodal status.
Conclusion
Clinical staging and pathologic grading are important prognostic factors in ONB. Dural resection in mKadish A and B did not show a significant survival benefit. Induction chemotherapy did not show a survival benefit, even after stage matching. |
| Keywords:
Esthesioneuroblastoma; Neoadjuvant Chemotherapy; Prognostic Factors; Survival Outcomes; Treatment Strategy |
|
|
|
Download PDF File
Full text via DOI
Download Citation 
